VAPOROX

Vaporox was formed to commercialize Vaporous Hyperoxia Therapy (VHT), a patented and FDA-510(k)-cleared technology that represents a breakthrough in treating 9 different types of skin wounds, including diabetic foot ulcers (DFUs), as well as amputations, burns, frostbite, gangrene, pressure ulcers (bed sores), and skin grafts. After establishing VHT as the preferred treatment for DFUs, Vaporox intends to look at extending its technology to treat other types of skin wounds and maladies, or licensing VHT to other medical device companies.